Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

Type 2 Diabetes Mellitus Clinical Trial

Official title:

Comparison of Neutral Protamine Hagedorn (NPH) and Lantus Based Insulin Regimen in the Management of Hypoglycemia in the Hospitalized Patients in Noncritical Care Setting

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT02189395
• Other study ID #: 437860
• Status: Terminated
• Phase: Phase 4
• First received: July 9, 2014
• Last updated: September 27, 2017
• Start date: April 2013
• Est. completion date: April 2017

Study information

• Verified date: September 2017
• Source: Riverside County Regional Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The goal of the current study is to determine difference in glycemic control between traditional split mix regimen with Neutral Protamine Hagedorn (NPH) and regular insulin vs basal bolus regimen with glargine and humalog in a population of type 2 diabetes commonly encountered in the investigators county hospital setting which include newly diagnosed type 2 patients and patients on relatively high dose of insulin (dose >0.4 units/kg body weight. Primary outcome of the study is to determine differences in glycemic control between treatment group as measured by the mean daily blood glucose. Secondary outcome is to measure number of hypoglycemic events, number of severe hypoglycemia and length of hospital stay.

Description:

The effect of insulin depends not only on the pharmacokinetics and pharmacodynamics of a particular preparation, but also on patient specific factors which includes state of inflammation, obesity etc. Although effect on glucose disposal is the central to insulin action, there could be differences of insulin action on other metabolic parameters. It is not known if there is a difference in suppression of inflammation with improved glycemic control which could vary with analog insulin. It is unknown if natural insulin (NPH, recombinant human insulin with protamine) differs from insulin analogs (glargine and detemir, made by substituting amino acid in the native sequence) in terms of metabolic outcome other than glucose disposal.

At this point it is uncertain if there is any clear benefit of use of lantus over NPH in inpatient glycemic management. Currently, both lantus and NPH based regimen is practiced in inpatient hospital setting. Current practice of inpatient insulin regimen is based more on familiarity of physicians with a particular insulin type and personal preference rather than evidenced based knowledge. Lantus is an expensive insulin preparation compared to NPH with uncertain benefit in inpatient setting. Current research proposal will compare this two insulin based regimen in the management of diabetes of hospitalized patients. Information obtained through this research will guide the investigators practice in this institution as well as in other institutions.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 52
• Est. completion date: April 2017
• Est. primary completion date: April 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Patients with type II diabetes regardless of duration of diagnosis with an admission blood glucose level between 140 mg/dL to 400 mg/dL will be included in the study.

• Other inclusion criteria are as follows:

• age 18-80 years old

• treated with diet alone

• any combination of oral anti-diabetic agents or insulin treatment with any dosage before admission.

Exclusion Criteria:

• Hyperglycemia without a known history of diabetes

• H/o recent cardiac surgery (within 6 months)

• Impaired renal function (glomerular filtration rate less than 45)

• History of diabetic ketoacidosis

• Diabetes mellitus type 1

• Pregnancy

• Patients on steroid treatment

• Known hypopituitarism or adrenal insufficiency

• Known hypoglycemia of unawareness

• Length of stay <48 h

• And severe liver disease and patent admitted in intensive care unit.

• Patients already received an insulin dose greater than 0.5 units/kg body weight after admission prior to initiation of study protocol will be excluded from the study.

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus, Type 2
• Hypoglycemia
• Type 2 Diabetes Mellitus

Intervention

Drug:
• NPH and regular insulin

• glargine and humalog

Locations

Country	Name	City	State
United States	Riverside County Regional Medical Center	Moreno Valley	California

Sponsors (1)

Lead Sponsor	Collaborator
Riverside County Regional Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	difference in glycemic control between treatment groups as measured by the mean daily blood glucose	Primary outcome of the study is to determine differences in glycemic control between treatment group as measured by the mean daily blood glucose	Duration of hospital stay, up to 24 weeks
Secondary	number of hypoglycemic events	number of hypoglycemic events	duration of hospital stay, up to 24 weeks